Opinion November 3, 2023
Paul Hastings Manages IPO for Lexeo Therapeutics: A Genetic Medicine Game-Changer
In a heart-pounding financial feat, Lexeo Therapeutics Inc., a trailblazing gene-therapy focused biotechnology firm, has unleashed a torrent of excitement…